Jump to main content
Jump to site search

Issue 4, 2016
Previous Article Next Article

Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy

Author affiliations

Abstract

Sepsis represents a systemic inflammatory response caused by microbial infection in blood. Herein, we present a novel comprehensive approach to mitigate inflammatory responses through broad spectrum removal of pathogens, leukocytes and cytokines based on biomimetic cell margination. Using a murine model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), we performed extracorporeal blood filtration with the developed microfluidic blood margination (μBM) device. Circulating bacteremia, leukocytes and cytokines in blood decreased post-filtration and significant attenuation of immune cell and cytokine responses were observed 3–5 days after intervention, indicating successful long-term immunomodulation. A dose-dependent effect on long-term immune cell count was also achieved by varying filtration time. As proof of concept for human therapy, the μBM device was scaled up to achieve ∼100-fold higher throughput (∼150 mL h−1). With further multiplexing, the μBM technique could be applied in clinical settings as an adjunctive treatment for sepsis and other inflammatory diseases.

Graphical abstract: Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy

Back to tab navigation

Supplementary files

Article information


Submitted
16 Sep 2015
Accepted
07 Jan 2016
First published
15 Jan 2016

Lab Chip, 2016,16, 688-699
Article type
Paper

Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy

H. W. Hou, L. Wu, D. P. Amador-Munoz, M. P. Vera, A. Coronata, J. A. Englert, B. D. Levy, R. M. Baron and J. Han, Lab Chip, 2016, 16, 688
DOI: 10.1039/C5LC01110H

Social activity

Search articles by author

Spotlight

Advertisements